29 June 2021
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Angelfish Investments plc
(To be renamed 1graine plc)
("Company")
RESULT OF GENERAL MEETING AND PROPOSALS
The Company is pleased to announce that at the General Meeting of Shareholders held yesterday, all resolutions were duly passed.
The Company's name will change to 1graine plc and the change of name will be effective once Companies House has issued a certificate of change of name (the "Certificate"). A further announcement confirming the change of name and new Company website will be made in due course. Upon issue of the Certificate, the Company's ordinary shares, shall be traded on AQSE Growth Market under the ticker "KING". The new ISIN number will be GB00BM9CKV18 and the SEDOL will be BM9CKV1.
The Co-Investment Rights
The Co-Investment Rights agreement with Excalibur Healthcare will become effective immediately. The Company has been granted the rights to co-invest in all healthcare and life-science investment opportunities sourced or invested into by Excalibur Healthcare Services.
Fundraising
With the Resolutions having been approved, the fundraising of £1,900,500 (73,644,237 ordinary shares) will now be processed.
The unconditional fundraise of £100,000 (3,874,992,734), Ordinary Shares will also now be allotted on a post-consolidation basis so that 3,874,993 Ordinary Shares will now be issued.
The existing Director's participation in the Subscription and Options is conditional on the publication of the Company's audited financial results to 31 December 2020 via a Regulatory Information Service provider.
Board Changes
The following new Directors will join the Board immediately:
Sir Professor Christopher Evans (aged 63) - Executive Chairman
Stephen "Steve" David Winfield (aged 28) - Executive Director
Martin Walton (aged 57) - Executive Director
Admission & Total Voting Rights
Following the issue of the 3,874,992,734 new Ordinary Shares (3,874,993 new ordinary shares on a post-consolidated basis) and the 73,644,237 Subscription Shares, the Company's issued ordinary share capital shall consist of 83,023,385 ordinary shares of 0.002 pence each. This number represents the total voting rights in the Company which may be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's ("FCA") Disclosure & Transparency Rules. The Subscription Shares shall rank pari passu in all respects with the existing ordinary shares of the company.
The Directors of the Company, who have issued this RIS announcement after due and careful enquiry, accept responsibility for its content.
Enquiries
Company :
Simon Grant-Rennick (Director)
Burns Singh Tennent-Bhohi (Director)
Office Line: +44 (0) 20 3778 0755
AQSE Growth Market Corporate Adviser
Peterhouse Capital Limited
Guy Miller / Mark Anwyl
Tel: +44 (0) 207 469 0930
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.